161 related articles for article (PubMed ID: 29417588)
1. Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer.
Lecavalier-Barsoum M; Chaudary N; Han K; Koritzinsky M; Hill R; Milosevic M
Int J Cancer; 2018 Sep; 143(5):1017-1028. PubMed ID: 29417588
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.
Chaudary N; Pintilie M; Jelveh S; Lindsay P; Hill RP; Milosevic M
Clin Cancer Res; 2017 Mar; 23(5):1242-1249. PubMed ID: 27697997
[No Abstract] [Full Text] [Related]
3. Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
Lecavalier-Barsoum M; Chaudary N; Han K; Pintilie M; Hill RP; Milosevic M
Br J Cancer; 2019 Jul; 121(3):249-256. PubMed ID: 31239542
[TBL] [Abstract][Full Text] [Related]
4. The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated With Radiation Therapy and Concurrent Chemotherapy.
Chaudary N; Hill RP; Stulik L; Milosevic M
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1317-1324. PubMed ID: 33771702
[TBL] [Abstract][Full Text] [Related]
5. Targeting the CXCL12/CXCR4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma].
Wei M; Liang LZ; Zhang CQ; Xiong Y; Zhang Y; Shen Y; Li JQ
Ai Zheng; 2007 Mar; 26(3):298-302. PubMed ID: 17355795
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
Ryu SY; Lee WM; Kim K; Park SI; Kim BJ; Kim MH; Choi SC; Cho CK; Nam BH; Lee ED
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e577-81. PubMed ID: 21840137
[TBL] [Abstract][Full Text] [Related]
9. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
10. Activation of CXCL12/CXCR4 renders colorectal cancer cells less sensitive to radiotherapy via up-regulating the expression of survivin.
Wang D; Jiao C; Zhu Y; Liang D; Zao M; Meng X; Gao J; He Y; Liu W; Hou J; Zhong Z; Cheng Z
Exp Biol Med (Maywood); 2017 Feb; 242(4):429-435. PubMed ID: 27798120
[TBL] [Abstract][Full Text] [Related]
11. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
Serkies K; Jassem J
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
[TBL] [Abstract][Full Text] [Related]
12. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
[TBL] [Abstract][Full Text] [Related]
13. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341).
Kamer S; Ren Q; Dicker AP
Arch Gynecol Obstet; 2009 Jan; 279(1):41-6. PubMed ID: 18461345
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-κB signaling in cervical cancer.
Chang YW; Chen MW; Chiu CF; Hong CC; Cheng CC; Hsiao M; Chen CA; Wei LH; Su JL
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S687-95. PubMed ID: 25047463
[TBL] [Abstract][Full Text] [Related]
15. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
17. FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells.
Li JL; Wang JP; Chang H; Deng SM; Du JH; Wang XX; Hu HJ; Li DY; Xu XB; Guo WQ; Song YH; Guo Z; Sun MX; Wu YW; Liu SB
Cancer Med; 2019 Dec; 8(18):7774-7780. PubMed ID: 31670906
[TBL] [Abstract][Full Text] [Related]
18. [Pelvic radiation with concurrent chemotherapy compared with pelvi and para-aortic radiation for high-risk cervical cancer. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. Cisplatin, radiation, and adjuvant hysterectomy for bulky stage Ib cervical carcinoma].
Nöel G; Mazeron JJ
Cancer Radiother; 1999; 3(4):345-7. PubMed ID: 10515699
[No Abstract] [Full Text] [Related]
19. Gene expression changes in residual advanced cervical cancer after radiotherapy: indicators of poor prognosis and radioresistance?
Fu ZC; Wang FM; Cai JM
Med Sci Monit; 2015 May; 21():1276-87. PubMed ID: 25940978
[TBL] [Abstract][Full Text] [Related]
20. [Current methods of chemoradiotherapy for locally advanced cervical cancer. Options for reduction of side-effects].
Póti Z; Mayer A
Orv Hetil; 2013 May; 154(21):803-9. PubMed ID: 23692874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
